University of Pennsylvania drives new discoveries in cancer immunotherapy research on an international scale, and pioneered the first FDA-approved CAR-T cell therapy. Penn’s award-winning doctors and scientists focus on training immune cells to recognize and hunt cancer cells. PICI at Penn extends this work and supports laboratory studies and clinical trials, recruitment of talented new faculty and opportunities for early-career investigators who will train at Penn. Carl June, MD | Director Saar Grill, MBBS, PhD, FRACP | Co-Director E. John Wherry, PhD | Co-Director All Investigators Related Our Impact, Press Release, Research Update For Advanced Pancreatic Cancer, Combining Immunotherapies with Chemotherapy Shows Early Promise in Reducing Tumor Size Clinical Trial The PRINCE Trial Research Update A Bubble of Hope for Cancer: the Exosome in Immunotherapy Press Release Parker Institute researchers publish first major scientific paper in Nature Announcement, Our Impact, Press Release PICI at ASCO: New Data. Big Impact. Top Honors. Announcement, Partner Highlight, Press Release New PICI Collaboration Bolsters Science-to-Market Edge Announcement, Partner Highlight, Press Release PICI, Immunai to Build Landmark Cancer Dataset Announcement, Our Impact PICI at AACR 2025: Data, Direction, Impact Announcement, Press Release Dr. Ira Mellman Joins PICI as President of Research
Our Impact, Press Release, Research Update For Advanced Pancreatic Cancer, Combining Immunotherapies with Chemotherapy Shows Early Promise in Reducing Tumor Size
Announcement, Partner Highlight, Press Release New PICI Collaboration Bolsters Science-to-Market Edge